Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer

• Published in: Frontiers in oncology 2023-06, Vol.13, p.1162820-1162820
• Main Authors: Mitsui, Yozo, Yamabe, Fumito, Hori, Shunsuke, Uetani, Masato, Aoki, Hiroshi, Sakurabayashi, Kei, Okawa, Mizuho, Kobayashi, Hideyuki, Nagao, Koichi, Nakajima, Koichi
• Format: Article
• Language: English
• Subjects: biomarker; C-reactive protein albumin ratio; metastatic castration-resistant prostate cancer (mCRPC); metastatic hormone sensitive prostate cancer; Oncology; time to castration resistance
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1162820

This study aimed to identify the prediction accuracy of the combination of C-reactive protein (CRP) albumin ratio (CAR) and time to castration resistance (TTCR) for overall survival (OS) following development of metastatic castration-resistant prostate cancer (mCRPC). Clinical data from 98 mCRPC patients treated at our institution from 2009 to 2021 were retrospectively evaluated. Optimal cutoff values for CAR and TTCR to predict lethality were generated by use of a receiver operating curve and Youden's index. The Kaplan-Meier method and Cox proportional hazard regression models for OS were used to analyze the prognostic capabilities of CAR and TTCR. Multiple multivariate Cox models were then constructed based on univariate analysis and their accuracy was validated using the concordance index. The optimal cutoff values for CAR at the time of mCRPC diagnosis and TTCR were 0.48 and 12 months, respectively. Kaplan-Meier curves indicated that patients with CAR >0.48 or TTCR